SAN FRANCISCO – November 03, 2026 -- Thryv Therapeutics Inc. has raised a $30 million Series B financing led by InClin, Inc., a global contract research organization, to move its SGK1 inhibitor THRV-1268 into a Phase 2a heart failure study that opens for enrollment in early 2027.

The round follows completion of enrollment in the first efficacy cohort of the Wave II Phase 2/3 study of THRV-1268 in Long QT Syndrome. It also follows a favorable review of available Wave II data by the study's Independent Data Monitoring Committee (IDMC).